CanniMed Therapeutics Inc. Adds to Executive Leadership TeamSeptember 15, 2017
CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) is pleased to announce that Howard Harkness and Allan Fowler have joined the Company’s executive leadership team. Mr. Harkness has been appointed Vice President of Marketing and Sales, and Mr. Fowler has joined as Vice President of Business Development and Investor Relations.
“It is the ideal time within the medical cannabis industry to announce the newest additions to our leadership team,” said Brent Zettl, President and CEO of CanniMed. “Howard and Allan possess talent and expertise that will continue to propel our Company to advance a number of critical growth initiatives. Branding, sales and education, along with a focus on both national and international expansion, have never been more important. The newest members of our leadership team will be instrumental in the Company’s ongoing success.”
Mr. Harkness brings a wealth of experience in directing, planning and implementing sales and marketing programs in the pharmaceutical, biotech and medical device markets. Prior to joining CanniMed, he was responsible for marketing and sales for Trudell Medical International, a privately owned respiratory medical device company. During his tenure, he established Trudell’s direct-to-market capabilities, including planning and executing sales and marketing programs to hospitals, hospital buying groups, physicians’ offices, clinics and pharmacy chain head offices. At CanniMed, Mr. Harkness will oversee the development and implementation of the Company’s branding strategy, enhancing sales operations and building a biopharmaceutical product portfolio targeting the domestic and international markets.
Mr. Fowler brings broad senior business experience to the Company, including business development, investor relations and financial management. Prior to joining CanniMed, Mr. Fowler was CFO of Mosaic Capital Corporation, a publicly-listed private equity company invested in a diversified portfolio of companies across Canada, and additionally held several other significant positions within the private equity arena. Mr. Fowler has deep business relationships within Canada and international markets, including Australia, and his new role with CanniMed will be to increase the visibility of the Company throughout the investment and business development communities.
About CanniMed Therapeutics Inc.
CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.
The Company, through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.
Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CanniMed Therapeutics Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks described in CanniMed Therapeutics Inc.’s documents filed with applicable Canadian securities regulatory authorities which may be viewed at www.sedar.com . The forward-looking statements included in this news release are made as of the date of this news release. CanniMed Therapeutics Inc. does not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities legislation.
For more information or to schedule an interview, please contact:
CanniMed Therapeutics Inc.
Dara Willis, (416) 836-9272